Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.58 |
| ▸ | CTSD | P07339 | 5/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3178567 | 1.00 | BACE1 (0.58) | BACE1CTSDCTSBBACE2ATM | |
| SCHEMBL3178543 | 0.88 | BACE1 (0.68) | BACE1CTSDCTSBBACE2 | |
| SCHEMBL3178533 | 0.88 | BACE1 (0.68) | BACE1CTSDCTSBBACE2 | |
| SCHEMBL13307745 | 0.86 | BACE1 (0.59) | BACE1CTSDCTSBBACE2ATM | |
| SCHEMBL13306616 | 0.85 | BACE1 (0.68) | BACE1CTSDCTSB | |
| SCHEMBL3355052 | 0.85 | BACE1 (0.68) | BACE1CTSDCTSB | |
| SCHEMBL13334080 | 0.85 | BACE1 (0.66) | BACE1CTSDCTSBBACE2 | |
| SCHEMBL13307641 | 0.85 | BACE1 (0.68) | BACE1CTSDCTSB | |
| SCHEMBL3349885 | 0.84 | BACE1 (0.65) | BACE1CTSDCTSBBACE2ATM | |
| SCHEMBL14201296 | 0.84 | BACE1 (0.68) | BACE1CTSDCTSBBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | JOHN VARGHESE | 2010-06-10 | — | — | US | disclosed |
| US-7645780-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7544717-B2 | 2-amino- and 2-thio- substituted 1,3-diaminopropanes | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7244725-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20060014737-A1 | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| US-20050267199-A1 | 2-Amino- and 2-thio- substituted 1,3-diaminopropanes | ELAN PHARMACEUTICALS, INC. | 2005-12-01 | — | — | US | disclosed |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | BACE1, BACE2, APP | BACE1 1/4885CTSD 185/4885CTSB 110/4885 |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | BACE1 1/4885CTSD 107/4885CTSB 73/4885 |
| US-20060014737-A1 | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors | DNPEP, ASPH, APP | BACE1 5/4885CTSD 95/4885CTSB 56/4885 |
| US-20050267199-A1 | 2-Amino- and 2-thio- substituted 1,3-diaminopropanes | BACE1, APP, BACE2 | BACE1 1/4885CTSD 311/4885CTSB 240/4885 |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | BACE1 1/4885CTSD 185/4885CTSB 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.